Circadian Technologies Limited is engaged in developing and commercializing therapies for cancer and eye diseases. The Company focuses on developing activities, which covers targets, including vascular endothelial growth factors (VEGF-C, VEGF-D and VEGF receptor-3). It develops therapies for the treatment of diseases associated with blood and lymphatic vessel growth, such as angiogenesis, lymphangiogenesis and vascular leakage. Its lead molecule, OPT-302, is in development stage and is a soluble form of VEGFR-3. Its OPT-302 blocks blood and lymphatic vessel growth, and inhibits vascular leakage. Its therapeutic product pipeline also includes VGX-100, a neutralizing monoclonal antibody for VEGF-C, and IMC-3C5, a neutralizing monoclonal antibody for VEGFR-3. The Company, through its subsidiary, Opthea Pty Ltd, is developing OPT-302 for the treatment of wet age-related macular degeneration (wet AMD). Its subsidiaries also include Ceres Oncology Pty Ltd and Vegenics Pty Ltd.